Psoriasis
Conditions
Brief summary
Psoriasis is an immune-mediated inflammatory skin disease characterized by the presence of erythematous and itchy plaques. Psoriasis has a multifactorial pathogenesis, environmental and genetic factors contribute to its development. Although interleukin-23 blockade has been shown to be highly effective in the treatment of psoriasis, relapses have occurred during therapy. Our study aims to identify the cellular source of key cytokines involved in disease recurrence or persistence of at least one psoriatic lesion in patients affected by moderate- severe psoriasis treated with an anti-IL-23 biologic drug. The immune infiltrate of resistant or relapsed plaques during anti-IL-23 therapy will be analysed from skin biopsies.
Interventions
PROCEDUREskin biopsy
punch biopsy (6 mm) of lesional psoriasis skin
Sponsors
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* moderate-severe psoriasis PASI\>10 * anti IL 23 biologic therapy for at least 6 months (for the group under treatment) * during therapy at least one area resistant to treatment or at least one flare of disease (for the group under treatment) * patients able to express informed consent
Exclusion criteria
* patients unable to express informed consent * patients with complete response to anti IL23, without resistant plaques or disease flare-ups
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identify the cellular source of key cytokines involved in disease recurrence or persistence of at least a psoriatic lesion | through study completion, an average of 1 year | Through the integration of multiparametric immunofluorescence staining with RNA in situ hybridization technology, our study aims to identify the cellular source of key cytokines involved in disease recurrence or persistence of at least one lesion psoriatic lesion in patients with moderate-severe psoriasis, undergoing treatment with anti-IL-23. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| immune biomarkers of sustained and prolonged response to treatment | through study completion, an average of 1 year | Identification of possible immune biomarkers of sustained and prolonged response to anti-IL-23 biological therapy that will include the expression profile of biomarkers related to tissue immune memory. |
Countries
Italy
Contacts
Primary ContactKetty Peris, Prof
Outcome results
None listed